trending Market Intelligence /marketintelligence/en/news-insights/trending/babOLMUoXM_jmuwtmmnByg2 content esgSubNav
In This List

Bio-Techne closes $43M equity investment in Astute Medical

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Bio-Techne closes $43M equity investment in Astute Medical

Bio-Techne Corp. made a $43 million equity investment in medical diagnostics company Astute Medical Inc.

The financing gives Bio-Techne certain manufacturing rights for future products and royalties on diagnostic tests containing Bio-Techne reagents. In exchange, Astute gains access to Bio-Techne's extensive libraries of antibodies and proteins to develop new diagnostic methodologies.

The investment was made as part of Bio-Techne's long-term plan to further its presence in the branded diagnostic market.